Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.80    0.00 (0.00%)
Bid:
1.60
Ask:
2.00
Spread: 0.40 (25.00%)
Market Cap: £7.87m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Holding(s) in Company

28 Oct 2025 16:04

RNS Number : 1715F
Renalytix PLC
28 October 2025
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Renalytix PLC

GB00BYWL4Y04

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

UBS Group AG - Investment Bank & Global Wealth Management

City and country of registered office (if applicable)

Zürich

Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

UBS AG

City and country of registered office (if applicable)

London, United Kingdom

5. Date on which the threshold was crossed or reached vi:

27 October 2025

6. Date on which issuer notified (DD/MM/YYYY):

28 October 2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.172754%

0.000000%

5.172754%

22,605,901

Position of previous notification (if

applicable)

8.002628%

0.000000%

8.002628%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYWL4Y04

22,605,901

5.172754%

SUBTOTAL 8. A

22,605,901

5.172754%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

UBS Group AG

UBS AG

5.172754%

5.172754%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Zurich, Switzerland

Date of completion

28.10.2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIRIVLTFIE
Date   Source Headline
29th May 20264:24 pmRNSHolding(s) in Company
27th May 202611:20 amRNSHolding(s) in Company
18th May 20263:52 pmRNSHolding(s) in Company
5th May 20263:26 pmRNSHolding(s) in Company
5th May 20269:39 amRNSHolding(s) in Company
1st May 20269:23 amRNSHolding(s) in Company
29th Apr 20264:17 pmRNSHolding(s) in Company
23rd Apr 202611:46 amRNSHolding(s) in Company
23rd Apr 202611:42 amRNSHolding(s) in Company
22nd Apr 20267:00 amRNSKey milestones achieved for kidneyintelX.dkd
16th Apr 20266:04 pmRNSHolding(s) in Company
16th Apr 20269:16 amRNSHolding(s) in Company
9th Apr 20264:29 pmRNSHolding(s) in Company
7th Apr 20265:25 pmRNSHolding(s) in Company
7th Apr 20265:24 pmRNSHolding(s) in Company
30th Mar 20263:41 pmRNSHolding(s) in Company
26th Mar 20267:00 amRNSHalf-year Report
18th Mar 20261:55 pmRNSHolding(s) in Company
17th Mar 202611:22 amRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
27th Feb 20267:00 amRNSHolding(s) in Company
13th Feb 20262:30 pmRNSFurther CEO Share Purchase
13th Feb 20267:00 amRNSDirector/PDMR Shareholding
12th Feb 20267:01 amRNSDirector/PDMR Share Purchase
12th Feb 20267:00 amRNSCEO Share Purchase
11th Feb 20267:00 amRNSH1 Trading update
21st Jan 20263:20 pmRNSHolding(s) in Company
15th Jan 20264:51 pmRNSHolding(s) in Company
12th Jan 20267:00 amRNSThree kidneyintelX.dkd Clinical Integrations
9th Jan 20262:43 pmRNSHolding(s) in Company
6th Jan 20264:28 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
17th Dec 20251:42 pmRNSHolding(s) in Company
16th Dec 20251:51 pmRNSHolding(s) in Company
9th Dec 202510:57 amRNSResult of AGM
9th Dec 20257:00 amRNSAGM Statement
27th Nov 20252:39 pmRNSHolding(s) in Company
25th Nov 20253:44 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSPlan to Implement ADS Ratio Change
12th Nov 20257:00 amRNSPivotal kidneyintelX.dkd data published
5th Nov 20254:02 pmRNSHolding(s) in Company
4th Nov 20256:05 pmRNSPublication of Annual Report & Notice of AGM
3rd Nov 202512:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSAudited Full Year Fiscal 2025 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.